Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Resverlogix, Medtronic sign DES (drug-eluting stent) licensing pact

This article was originally published in Clinica

Executive Summary

In a bid to expand its drug-eluting stent (DES) portfolio, Medtronic has entered a licensing deal with Canadian biotech company Resverlogix whereby the medtech giant will gain exclusive, worldwide access to the latter's ReVas cardiovascular drug programme. The agreement will see Calgary, Alberta-based Resverlogix receive up to Can$340m (US$291m) in milestone payments and royalties from its new partner.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT052379

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel